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Chronic oxytocin administration
as a treatment against impaired
leptin signaling or leptin resistance
in obesity
Jordi Altirriba*, Anne-Laure Poher and Françoise Rohner-Jeanrenaud
Laboratory of Metabolism, Department of Internal Medicine Specialties, Faculty of Medicine, University of Geneva, Geneva,
Switzerland
This review summarizes the existing literature on the effects of oxytocin administration
in the treatment of obesity in different animal models and in humans, focusing on the
central control of food intake, the oxytocin effects on adipose tissue, and the relationships
between oxytocin and leptin. Oxytocin is a hypothalamic nonapeptide synthesized mainly
in the paraventricular and supraoptic nuclei projecting to the pituitary, where it reaches
the peripheral circulation, as well as to other brain regions. Moreover, leptin modulates
oxytocin levels and activates oxytocin neurons in the hypothalamic paraventricular
nucleus, which innervates the nucleus of the solitary tract, partly responsible for the
brain-elicited oxytocin effects. Taking into account that oxytocin is located downstream
leptin, it was hypothesized that oxytocin treatment would be effective in decreasing
body weight in leptin-resistant DIO animals, as well as in those with leptin or with leptin
receptor deficiency. Several groups have demonstrated that in such animal models (rats,
mice, and rhesus monkeys), central or peripheral oxytocin administration decreases
body weight, mainly due to a decrease in fat mass, demonstrating that an oxytocin
treatment is able to partly overcome leptin deficiency or resistance. Moreover, a pilot
clinical study demonstrated the efficiency of oxytocin in the treatment of obesity in
human subjects, confirming the results obtained in the different animal models. Larger
multicenter studies are now needed to determine whether the beneficial effects of oxytocin
treatment can apply not only to obese but also to type 2 diabetic patients. These
studies should also shed some light on the molecular mechanisms of oxytocin action in
humans.
Keywords: oxytocin, leptin, adipocyte, obesity, diabetes
1. Introduction
According to the World Health Organization, 2.8 million people die worldwide due to overweight
or obesity, which represents one of the five leading global risks for mortality (1). Aging is another
situation that contributes to the development of overweight or obesity. Indeed, it is well known that
the body mass index tends to increase throughout adulthood, to level off from the age of 50 onward
(2). Moreover, the presence of overweight or obesity in young and middle age was reported to result
in adverse consequences for health care costs in older age (3).
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Overall, the key component of the obesity epidemic is long-
term dysregulation of energy balance comprising increased
energy intake and/or reduced energy expenditure. Despite active
research and impressive improvements in the understanding of
the regulation of energy balance, there are only a very limited
number of drugs that can be used for the efficient treatment
of obesity and its comorbidities. Given the well-known state of
leptin resistance, present in the vast majority of overweight/obese
subjects, together with the fact that leptin exerts a whole array of
beneficial effects on bodyweight homeostasis, one of the common
approaches is to identify leptin targets that are able to mimic
leptin’s effects, thereby bypassing leptin resistance. Along this
line, oxytocin was recently considered as a potential interesting
candidate, although it was historically recognized for its role in
parturition and lactation (4). The aim of this review is to sum-
marize the existing literature demonstrating the effects of oxy-
tocin on the feeding behavior and peripheral metabolism, as well
as to describe the interactions between oxytocin and the leptin
signaling pathway.
Virtually, all vertebrate species were found to have an oxytocin-
like nonapeptide that supports reproductive functions (5, 6). This
impressive evolutionary conservation illustrates the significance
of oxytocin in the survival of species. In mammals, oxytocin is
synthesized mainly in the central nervous system, within both the
magnocellular and parvocellular neurons of the paraventricular
nucleus (PVN), as well as by the magnocellular neurons of the
supraoptic nucleus (SON) in the hypothalamus. Unlike magno-
cellular oxytocin neurons, which project to the neurohypophysis
(posterior pituitary), where they secrete oxytocin into the circu-
lation, parvocellular oxytocin neurons of the PVN project cen-
trally to various brain areas, including the arcuate nucleus of the
hypothalamus (ARC) (7), the ventral tegmental area, the nucleus
of the solitary tract (NTS), and the spinal cord (5, 6). Oxytocin
release also occurs locally in the SON and PVN via somato-
dendritics. Several peripheral organs, such as the ovary, uterus,
placenta, testis, thymus, kidney, heart, blood vessels, skin, and
the gastrointestinal (GI) tract also synthesize oxytocin, although
to a lesser extent than hypothalamic neurons [for reviews, see
Ref. (5, 6, 8)]. To date, only one oxytocin receptor (OXTR) type
has been identified. Its wide distribution within the brain (e.g.,
basal ganglia, hypothalamus, nuclei of the hindbrain), as well
as in various peripheral tissues (e.g., heart, thymus, pancreas,
adipocytes, and GI tract) (5) is in keeping with its large variety
of physiological actions [for review, see Ref. (5)].
In 1989, Arletti et al. described that oxytocin administra-
tion (intraperitoneally or intracerebroventricularly) reduced food
intake in rats, due to both a reduced meal size and an increased
latency to feeding (9). Oxytocin is now well recognized as an
anorexigenic neuropeptide, which effects are mediated by reduc-
ing gastric emptying and GI transit, as well as by suppressing
the feeding reward circuit (4, 10). Furthermore, oxytocin and
OXTR knockout mice were shown to develop late-onset obesity
(11, 12), without alterations in food intake, pointing to the fact
that oxytocin is controllingmetabolic homeostasis, not only via an
effect on food intake but also by modulating energy expenditure
(11, 13) [for review, see Ref. (4)]. In keeping with the roles of oxy-
tocin described in rodents (see below), patients with Prader–Willi
syndrome (whose main characteristics are cognitive disabilities,
chronic food craving, and morbid obesity) seem to present a
deficit in the oxytocin producing neurons of the PVN (14), prob-
ably due to a loss of function or deletion of SIM1, a transcription
factor controlling the expression of the OXT gene (15, 16).
Summary
Oxytocin can be considered as an anorexigenic peptide. Lack of
oxytocin leads to the development of obesity in rodents, as well
as in humans. This is partly independent of its effect on food
intake, suggesting an additional role of oxytocin in the regulation
of metabolic homeostasis.
2. Central Oxytocin Circuits and Interaction
with Leptin in the Control of Food Intake
Different oxytocin neuron populations may fulfill different func-
tions. Their interactions with leptin also appear to be specific for
some distinct neurons. Close examination of the literature in the
field allows to unravel the importance of precise leptin–oxytocin
circuits in the regulation of food intake.
2.1. PVN to NTS Oxytocin Circuit
Accumulating evidence suggests that oxytocin neurons in the
PVN mediate the anorexigenic effect of leptin (Figure 1). Thus,
the oxytocin synthesizing neurons in the PVN exhibit a strong
expression of the leptin receptor (17). Central leptin administra-
tion was shown to activate parvocellular oxytocin neurons of the
PVN, which project to the NTS (18–20), where they are known
to innervate POMC/CART neurons (21, 22). The low Oxt gene
expression observed in the PVN during fasting was recovered
after peripheral leptin administration (20, 23). Additionally, the
leptin effect in decreasing food intake was partially blunted in
adult mice with ablation of oxytocin neurons (24) and it was
prevented by the injection of an OXTR antagonist within the
fourth ventricle (19) (close to the NTS). Finally, the involvement
of oxytocin neurons in leptin action was substantiated in mice
with deletion of Socs3 (an inhibitor of the Jak-Stat leptin signaling
pathway) in the mediobasal hypothalamus (25), which includes
the PVN. Indeed, as a result of improved leptin signaling, these
mice exhibited decreased food intake and body weight. Interest-
ingly, the oxytocin content of the dorsal vagal complex (including
the NTS) was increased in response to leptin administration in
these mice, and the leptin-induced decrease in food intake was
abolished by injection of an OXTR antagonist into the NTS (25).
Collectively, these data suggest that oxytocin neurons of the PVN
could mediate the leptin-activated hindbrain (NTS)-containing
satiety circuit.
One of the ways by which leptin was reported to decrease food
intake is by enhancing the efficiency of gut-derived anorexigenic
hormones, such as cholecystokinin (CCK) (26). Thus, in line with
a role of oxytocin as a mediator of leptin’s effect on food intake, it
was shown that the satiety effect of CCK is partly blunted by the
central injection of an OXTR antagonist or by destruction of the
OXTR expressing neurons in the NTS (27–29). In contrast, other
data obtained in oxytocin-deficient mice showed that oxytocin is
dispensable for feeding inhibition by CCK (24, 30). A possible
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FIGURE 1 | Representative scheme of the oxytocin neuronal circuits
controlling food intake. Leptin, through the leptin receptor (LepR), activates
oxytocin (Oxt) neurons in the hypothalamic paraventricular nucleus (PVN) and
POMC/CART neurons in the hypothalamic arcuate nucleus (ARC), whereas it
inhibits AgRP/NPY neurons in the ARC. Once oxytocin neurons are activated,
they are innervating and activating POMC/CART neurons in the hypothalamic
ARC nucleus and the hindbrain NTS nucleus (which is receiving also
innervation from the gut), leading to a decrease in food intake. Moreover,
activation of oxytocin neurons also triggers a negative feedback loop as PVN
oxytocin neurons innervate AgRP/NPY neurons in the ARC nucleus, which
inhibit oxytocin neurons in the PVN. At last, oxytocin neurons innervate the
posterior pituitary and their activation leads to the secretion of oxytocin into
the circulation, a way by which oxytocin can reach its target tissues, such as
white adipose tissue. Arrow-headed lines and bar-headed lines indicate
activation and inhibition, respectively. Oxytocin neurons and innervations are
drawn in red, POMC/CART neurons in green, AgRP/NPY neurons in blue,
leptin protein in purple circles, and oxytocin protein in red circles.
Abbreviations: Oxt, oxytocin; POMC, pro-opiomelanocortin; CART, cocaine-
and amphetamine-regulated transcript; AgRP, agouti-related protein; NPY,
neuropeptide Y; CCK, cholecystokinin; LepR, leptin receptor; OxtR, oxytocin
receptor; ARC, arcuate nucleus; PVN, paraventricular nucleus; NTS, nucleus
of the solitary tract.
explanation that could reconcile both types of results (OXTR
antagonist and OXTR cell ablation vs. oxytocin knockout) is
that the oxytocin antagonist used (d(CH2)5[Tyr(Me)2,Thr4,Tyr-
NH2(9)] OVT) (27–29) is an inverse agonist, which would not
only block the oxytocin signal but also inhibit the neurons, which
express the OXTR. It is also possible that, in oxytocin knockout
mice, compensatory mechanisms may offset the absence of oxy-
tocin. Further studies are, however, needed to clarify the role of
oxytocin on the anorexigenic signal from gut-derived hormones.
2.2. PVN to ARC Oxytocin Circuit
In addition to PVN oxytocin neurons projecting to the NTS, other
oxytocin neurons in the PVN also innervate POMC and AgRP
neurons in the ARC (7). Moreover, it was reported that AgRP
neurons target and inhibit oxytocin neurons (31), constituting a
short feedback loop system in the hypothalamic control of food
intake. It should be mentioned, however, that intra-ARC oxytocin
administration decreased food intake to a lesser extent than lateral
ventricle injection, suggesting that ARC activation only partially
mediates the anorexigenic effect of oxytocin (7).
2.3. SON Oxytocin Neurons
With regard to the oxytocin neurons in the SON, they also display
a high expression of the leptin receptor (17). However, the leptin’s
effects on oxytocin in this nucleus are not clear. Thus, icv leptin
administration did not modify the Oxt gene expression in SON
neurons (32), neither did it activate OXT neurons in this nucleus,
as assessed by the measurement of c-fos expression (19). In addi-
tion, leptin was shown to exert either inhibitory or stimulatory
effects on the electrical activity of SON oxytocin neurons as stud-
ied in brain slices, or in vivo (i.v. administration in rats) (33, 34)
respectively. Further studies are required to understand the role
of oxytocin in the SON, although SON oxytocin neurons do not
appear to be involved in the control of food intake.
Summary
It appears that among the hypothalamic oxytocin neurons
involved in the control of food intake, those projecting from the
PVN to the NTS are the most important ones in mediating the
leptin’s effect.
3. Oxytocin Treatment in Animal Models of
Obesity and Diabetes: A Way to Overcome
Leptin Resistance?
Leptin administration to lean mice and rats leads to decreased
food intake and body weight, effects that are blunted in obese
rodents (35, 36). Moreover, diet-induced obese rodents are well
known to display high-circulating leptin levels, reflecting their
increased fat mass. Together, these data imply that obesity is asso-
ciated with a state of leptin resistance (37). Taking into account
that oxytocin is located downstream of leptin, mediating part of
its effects, it would be expected that oxytocin treatment would
be effective in decreasing body weight in leptin-resistant DIO
animals, as well as in those with leptin or with leptin receptor
deficiency.
3.1. Diet-Induced Obese Rodents
Recent data demonstrate that oxytocin treatment (subcutaneous
or intracerebroventricular) of DIOmice, rats and rhesus monkeys
was able to decrease body weight, mainly due to a decrease in
fat mass, with a concomitant improvement in glucose tolerance
and insulin sensitivity (38–42). Additional results obtained using
a pair-feeding paradigm or the use of low oxytocin doses (which
did not alter food intake) allowed concluding that at least part
of the body weight-lowering effect of oxytocin was independent
from changes in food intake (38, 39). It is noteworthy at that
point that the OXTR is highly expressed in adipose tissue [at a
similar level as in most of the classical oxytocin target tissues (43,
44)] and is upregulated in some mice models of obesity (44, 45).
This could explain the occurrence of oxytocin effects on adipose
tissue, as well as the difference between the effects of the oxytocin
treatment in lean and obese animals. Indeed, it was observed that
chronic oxytocin administration to lean mice was almost without
any effect after the first day of treatment (during which a decrease
in food intake and body weight was noted) (44).
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3.2. Rodents with Leptin Receptor Deficiency or
with Impaired Leptin Receptor Signaling
As alluded to above, oxytocin administration was also success-
ful in treating obesity in animal models of leptin deficiency or
reduced leptin receptor signaling [Zucker rats (21), Koletsky rats
(41), ob/ob mice (44), and db/db mice (22, 46)]. Thus, 2 weeks
of subcutaneous oxytocin infusion to ob/ob mice decreased body
weight gain, mainly due to an effect on the fat mass. This was
accompanied by a decrease in food intake, which was mainly
observed during the first week of the treatment. Surprisingly,
glucose tolerance of oxytocin-treated ob/ob mice was wors-
ened, probably due to an increased activity of the hypothala-
mic–pituitary–adrenal axis, which led to increased corticosterone
levels and enhanced hepatic gluconeogenesis (44). Interestingly,
longer oxytocin treatment (12weeks) in db/db mice also induced
a decrease in body weight gain with a decrease in the fat mass,
without any change in food intake. In contrast to ob/ob animals,
oxytocin-treated db/dbmice exhibited improved glucose tolerance
and insulin sensitivity (46).
3.3. Oxytocin Treatment in Other Rodent
Animal Models
Oxytocin treatment was also demonstrated to exert beneficial
effects in other animal models, improving glucose metabolism in
a diabetic model of pancreatic beta cell ablation by streptozotocin
(47) and decreasing fat mass gain in ovarectomized mice (48).
Summary
Oxytocin treatment is able to overcome leptin resistance or lep-
tin deficiency as it decreases body weight and fat mass in DIO
animals, as well as in rodents with leptin deficiency or reduced
leptin receptor signaling. In most experimental conditions, glu-
cose metabolism is improved by the oxytocin treatment, except
during short-term experiments in leptin-deficient mice.
4. Adipose Tissue as the Main Target of
Oxytocin Action in Obesity
Adipose tissue seems to be one of the main targets of oxytocin
in obesity, as the decrease in fat mass, in response to an in vivo
oxytocin treatment, was observed in all the different models of
rodent obesity studied so far (38, 39, 44, 46). However, considering
data obtained in vitro, ex vivo, or in vivo during acute or chronic
experiments, the reported results are contradictory.
4.1. In Vitro
In ex vivo experiments with adipose tissue or in cell cultures, oxy-
tocin was without any effect on lipid metabolism in rabbit adipose
tissue (49), whereas it reportedly increased lipogenesis (50, 51)
or lipolysis (38) in rat adipocytes. It was also demonstrated that
oxytocin inhibits adipocyte differentiation (52), increases glucose
oxidation, and stimulates pyruvate dehydrogenase activity (53).
4.2. In Vivo
In acute in vivo experiments, oxytocin administration resulted in
highly variable changes in non-esterified fatty acid (NEFA) and
triglyceride (TG) levels, according to the experimental conditions
used (e.g., sex, timing, feeding conditions, etc.) (54). Another
acute study indicated that oxytocin increased circulating NEFA
levels in dehydrated, but not in normally hydrated rats (55).
In chronic in vivo studies, it was shown that 15 days of treat-
ment with oxytocin enhanced lipolysis in DIO rats (38) and pro-
moted futile cycling (increase in both lipolysis and glycerogenesis)
in ob/ob mice (44). In lean animals, such a chronic treatment
increased adipogenesis in rats (56) and was without any effect in
mice (44). Interestingly, a much longer treatment (12weeks) was
reported to decrease the size of adipocytes, the mass of fat pads, as
well as to induce browning of white adipose tissue (i.e., presence of
brown or beige/brite adipocytes in white adipose depots) in lean
and obese db/dbmice (46).
In humans, while acute oxytocin injection produced an increase
in NEFA levels a few days after delivery (57), it resulted in
decreasedNEFA levels in non-pregnant healthy subjects (58). Fur-
thermore, chronic treatment of obese humans with nasal oxytocin
delivery did not significantly modify the TG levels, although there
was some trend toward a decrease in this parameter (47).
4.3. Possible Explanations for the Contrary
Results Obtained in Different Experimental
Setups
As detailed above, although in vivo oxytocin treatment appears
to consistently reduce fat mass in several models of obesity,
discrepant results pertaining to oxytocin effects on glucose
metabolism were observed. Concerning oxytocin effects on adi-
pose tissue, conflicting results were reported depending on the
experimental approach used (in vitro, ex vivo, in vivo).
One of the main reasons underlying the description of dis-
crepant results is the use of different models, doses, and dura-
tions of the oxytocin treatments. Alternatively, as suggested by
Muchmore and colleagues (59), the contradictory data could arise
from the existence of low- and high-affinity OXTRs with oppo-
site effects in response to their activation. Thus, low-oxytocin
levels would exert insulin-like activities through interaction with
high-affinity OXTRs, while at high concentrations, oxytocin
would inhibit glycogen deposition (likely through an activation
of glycogenolysis) and induce lipolysis, through its action on the
low-affinity receptors (59). It should be mentioned at that point
that, although the hypothesis of dose-dependent varying affinity
of oxytocin for its receptor is interesting, it was postulated more
than 30 years ago using an in vitro approach and was not validated
further since then.
Another important variable, which could influence the in vivo
oxytocin effects, is the type of diet consumed. Indeed, bymodulat-
ing the membrane composition (60), it is conceivable that the diet
may modulate the affinity of oxytocin for its receptor. This was
actually demonstrated in the presence of divalent cations (such
as magnesium) or cholesterol (5) and could occur when animals
are fed a high-fat diet to induce obesity, glucose intolerance, and
insulin resistance.
Differences in the expression of the OXTR (44, 45), as well as
in oxytocinase activity in adipose tissue (61) could also modulate
the type of oxytocin effects on glucose or lipid metabolism.
At last, it has been demonstrated that oxytocin neurons
innervate white adipose tissue through the sympathetic nervous
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system (62) and oxytocin knockout mice display a decreased sym-
pathetic tone (12). Altogether, oxytocin may therefore influence
adipose tissue metabolism both by direct and indirect action on
this tissue via the sympathetic nervous system. Therefore, the pos-
sible different sympathetic tone in the various models used could
potentially also explain some of the divergent results obtained.
Summary
Although the data in non-obese animals and in in vitro exper-
iments bring about some contradictory results, it is clear that
oxytocin treatment in obese animals decreases the fat mass. In
most instances, this is accompanied by improvements in glucose
metabolism. The mechanisms underlying these beneficial effects
remain to be determined.
5. Oxytocin Treatment in Obese Patients
Conflicting literature exists regarding the fact that circulating
oxytocin levels are increased (63), unchanged (64), or decreased
in obese (65) compared to lean human subjects. Moreover, highly
variable results were reported using different types of measure-
ments (66–68). This is an important issue as it leads to different
conclusions about the activity of the oxytocin system in human
obesity. This should prompt us to urgently define a standard and
reliable method allowing drawing relevant conclusions on that
topic.
Independently from this issue and taking into consideration
that part of the leptin actions seems to be mediated by oxytocin
(19), that chronic oxytocin treatment exerts promising effects on
obesity and diabetes in various rodentmodels, as described above,
it was hypothesized that oxytocin treatment could bypass the well-
described leptin resistance, present not only in animals but also in
obese human subjects (69).
As of now, two studies have been performed to determine the
effects of oxytocin on food intake, body weight, and metabolic
function in lean (70) and obese (47) volunteers. In lean healthy
men (70), a single dose of 24 IU of intranasal oxytocin administra-
tion was shown to inhibit the reward – but not the hunger-driven
eating, attenuating basal and postprandial levels of adrenocorti-
cotropic hormone and of cortisol, and decreasing the postpran-
drial rise in plasma glucose, without modifying energy expendi-
ture. Most interestingly, a clinical trial was performed by Zhang
et al. (47), whereby intranasal oxytocin was administered to obese
patients (BMI 30–36) at a dose of 24 IU, four times a day during
8weeks. This treatment led to a significant and constant decrease
in body weight (almost 9 kg) with a concomitant decrease in total-
and LDL-cholesterol. It is noteworthy that this clinical trial was
performed in male and female volunteers (pregnant and lactating
females excluded) and that no adverse effect was described, rein-
forcing the fact that this treatment seems to be safe and effective
in both sexes.
Summary
The beneficial effects of oxytocin treatment on bodyweight home-
ostasis obtained in animal models of obesity seem to apply to
human obesity as well.
6. Oxytocin and Aging
Few data are available as yet on the oxytocin system during aging.
Studies reported no change in hypothalamic oxytocin content in
old rats (71), total number of oxytocin neurons in old human
subjects (72), or plasma oxytocin levels in aged rats or humans
(73–75). This is in contrast with very recent data demonstrat-
ing a decrease in oxytocin circulating levels in aged mice (76),
pointing to possible species differences.Moreover, it has been pro-
posed that PVN oxytocin secretion is increased in aged rats (73),
which would fit with the decreased food intake that accompanies
aging (77).
7. Future Perspectives
In view of the small cohort of the clinical trial mentioned above, in
which oxytocin was administered to obese patients (9 subjects in
the oxytocin-treated group and 11 subjects in the placebo-treated
one) (47), larger multicenter clinical trials should be performed,
in order to confirm the results and extent the conclusions. More-
over, these clinical trials should include not only obese but also
type 2 diabetic patients, as the study by Zhang and collaborators
(47) pointed to a tendency toward improvements in postprandial
glucose and insulin levels in the oxytocin-treated group of obese
subjects. This would also fit the observations that rodent models
of type 2 diabetes (DIO rats and mice) exhibited improvements in
glucose intolerance and insulin resistance in response to oxytocin
treatment. Future studies should also shed some light on the
molecular mechanisms by which oxytocin treatment can exert its
beneficial effects.
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